Develops cancer drugs for nasopharyngeal carcinoma.
Jun 2026Revenue $50.9M/yrExpenses $210M/yr
No trendCash runway ≈ 7 months from Jun 2026
Figures by year
When will Coherus Oncology be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $50.9M and expenses $210M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $42.2M | $223M | −$181M |
| Dec 2024 | $26.4M | $226M | −$200M |
| Dec 2023 | $257M | $460M | −$203M |
| Dec 2022 | $211M | $468M | −$257M |
| Dec 2021 | $327M | $590M | −$264M |
| Dec 2020 | $476M | $320M | $156M |
| Dec 2019 | $356M | $248M | $108M |
| Dec 2018 | $0.00 | $204M | −$204M |
| Dec 2017 | $1.56M | $234M | −$232M |
| Dec 2016 | $189M | $305M | −$116M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.